ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab



Status:Completed
Conditions:Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:2 - 20
Updated:2/24/2018
Start Date:November 17, 2014
End Date:September 25, 2017

Use our guide to learn which trials are right for you!

An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

The purpose of this study is to evaluate the efficacy observed with canakinumab dose
reduction in a subgroup of patients in the extension study CACZ885G2301E1.

This two-part open-label study will assess 2 different canakinumab taper regimens in patients
with clinical remission (inactive disease for at least 24 continuous weeks) on canakinumab
treatment without concomitant corticosteroids (CS) or methotrexate (MTX). The study will also
collect long term safety and tolerability data on SJIA patients treated with canakinumab.

Inclusion Criteria:

Cohort 1:

• Patients who are receiving canakinumab treatment (4 mg/kg every 4 weeks) for Systemic
Juvenile Idiopathic Arthritis (SJIA) and have inactive disease at the last visit in Study
CACZ885G2301E1

Cohort 2:

- Confirmed diagnosis of SJIA as per International League Against Rheumatism (ILAR)
definition that must have occurred at least 2 months prior to enrollment with an onset
of disease < 16 years of age.

- Active SJIA defined as having 2 or more of the following:

- Documented spiking, intermittent fever (body temperature > 38°C) for at least 1 day
within 1 week before first canakinumab dose;

- At least 2 joints with active arthritis

- C-reactive protein (CRP) > 30 mg/L (normal range < 10 mg/L)

- Rash due to SJIA

- Serositis

- Lymphadenopathy

- Hepatosplenomegaly

- Negative TB screen (QuantiFERON or, if required by local guidelines, Purified Protein
Derivative).

Exclusion Criteria:

- With active or recurrent bacterial, fungal or viral infection at the time of
enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV)
infection, Hepatitis B and Hepatitis C infection.

- With underlying metabolic, renal, hepatic, infectious or gastrointestinal conditions
which in the opinion of the investigator immunocompromises the patient and /or places
the patient at unacceptable risk for participation.

- With neutropenia (absolute neutrophil count < 1500/mm3) at screening.
We found this trial at
3
sites
Columbus, Ohio 43205
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Vienna,
Click here to add this to my saved trials